

Charity registration number 1032256

**THE ASSOCIATION OF CANCER PHYSICIANS
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023**

THE ASSOCIATION OF CANCER PHYSICIANS

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	Dr A Jones Professor R Begent
Secretary	Prof. S Ahmed
Charity number	1032256
Principal address	c/o Mrs A Norton Department of Medicine Royal Marsden Hospital Downs Road, Sutton Surrey SM2 5PT
Independent examiner	Rouse Partners LLP 55 Station Road Beaconsfield Buckinghamshire United Kingdom HP9 1QL
Bankers	National Westminster Bank Plc

THE ASSOCIATION OF CANCER PHYSICIANS

CONTENTS

	Page
Trustees report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Balance sheet	7
Notes to the accounts	8 - 15

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

The trustees present their annual report and financial statements for the year ended 31 December 2023.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the constitution's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2015)"

Objectives and activities

The objectives of the Association of Cancer Physicians (ACP) are to advance the study and practice of cancer medicine (medical oncology), to represent the interests of medical oncologists and to foster the raising of standards in medical care for cancer patients. It is also the aim to facilitate contact between members of the Association and other individuals and organisations concerned with the study and treatment of cancer and with the public at large.

Applications for membership are approved by the Executive Committee and ratified at the AGM. Members and officers of the Executive Committee are nominated by the membership in line with the Constitution and Rules (updated 2013) and a vote of eligible members is organised in the event of a surplus of nominations for the vacant positions. The Chair is appointed for a period of three years that may be extended for a second term of office. The Executive Committee includes Officers in addition to regional representatives and other designated roles. There are up to three representatives of Cancer Physicians in training and one representative of the New Consultants Group on the Executive Committee. Professor David Cunningham took over as Chair of the ACP in November 2017 and Professor Samreen Ahmed is the current Honorary Secretary. Professor Helena Earl is the Honorary President.

Public benefit

The trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the constitution should undertake.

Achievements and performance

Significant activities and achievements against objectives

During 2023, the Association of Cancer Physicians continued to support a wide range of activities to advance the study and practice of cancer medicine and to help raise standards of medical care for patients.

The ACP contracts with SAS, an association management company, to provide support for the organisation of the ACP's programme of educational events, in addition to managing its membership activities and collection of subscriptions. The ACP AGM was held remotely by Zoom in October 2023, with good attendance. The Executive Committee has found that a virtual AGM helps to facilitate better participation and interaction with the membership from across the UK, in addition to reducing travel for members and reducing costs for all. The meeting is also recorded for members unable to join the live event.

Involvement in and support for medical oncology training, including teaching and education, remains a high priority for the ACP and in 2023 continued to hold both online and face to face educational events. In November the ACP collaborated with the UK Acute Oncology Society to hold a one-day meeting in Leeds "Acute Oncology: Challenges and Opportunities". This meeting brought together a panel of multidisciplinary speakers to address some of the dilemmas faced by everyone working in Acute Oncology. There was a focus on how acute oncology fits into the medical oncology curriculum and the current NHS landscape, and how cancer professionals can work together to keep patients safe during challenging times for cancer services in the NHS. In addition, there were talks on patient pathways and leadership of acute oncology services, with practical and interactive MDT sessions discussing the management of oncology-related emergencies and some difficult clinical scenarios. The meeting was well attended and feedback excellent. The Acute Oncology day was followed by the annual trainees weekend, at the same venue in Leeds. The weekend provides the medical oncology trainees a valuable opportunity to learn about wider aspects of oncology, important updates on treatments and to network with fellow oncologists from across the UK. They can gain support and learning from peers and hear from leading experts in the field. With the support of pharmaceutical sponsorship, the ACP kept the meeting free of charge for members to attend.

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

The ACP recognises that entry from trainee into consultant grade can be a challenging time for members as they learn to take on leadership and management responsibilities while taking charge of their clinical workload. To help medical oncologists through this difficult time the ACP has established an annual New Consultants Group (NCG) Meeting. Providing peer support through networking opportunities, together with targeted lectures, the meeting is aimed at all medical oncology consultants within 5 years of their first substantive consultant appointment in addition to trainees in the final 6 months of their training. These very popular meetings have now been run for nearly 20 years and, after a brief hiatus due to Covid, reverted to a spring face to face meeting in Birmingham in March 2023. With the support of pharmaceutical sponsorship, the ACP keeps these meetings free of charge for members to attend.

The ACP collaborated with MCI, a global communications company, to host the UK's only officially licensed Best of ASCO® Event. The livestreamed cross-tumour event summarised the most significant treatment advances presented at the 2023 ASCO Meeting in Chicago. Chaired by Professors Andrew Wardley and Samreen Ahmed, a faculty of leading experts provided a comprehensive overview of ASCO 2023 including plenaries and breakout sessions by tumour site, focused on key disease sites most relevant to UK oncologists.

The ACP was closely involved in the revision of the medical oncology curriculum, overseen by the JRCPTB, as required by the GMC, with the new curriculum implemented in August 2021. Trainees in medical oncology have to take and pass an exam (Specialist Certificate Exam – SCE), to demonstrate that they have sufficient knowledge to practise safely and competently as consultants. To provide trainees with additional support with studying for the exam, the ACP also prepared a new evidence-based resource to aid revision and support further learning “500 SBAs for the Medical Oncology Specialty Certificate Exam” was published in 2022 and, due to the fast pace in the development of new therapies in oncology, an updated edition is being prepared. The book contains questions and answers on the current investigations and management in UK cancer clinical practice. Trainees have found the book very useful to help with exam preparation. The ACP supported the costs of this publication and an agreement with the publishers, EBN Health, also allowed members to benefit from a discount on the purchase price.

The ACP continues to advocate for an expansion in the cancer workforce. Demand for systemic therapy has been increasing year on year, and this growth is expected to continue, due to the pressures of an aging population, an increased incidence of cancer, combined with welcome but rapid advances in genomics and new therapeutic options. The specialty welcomed a further significant increase in specialty training numbers in medical oncology allocated in 2023, however feels strongly that this expansion needs to be continued in future years to develop a workforce to deliver world leading cancer services in the future. There are widespread concerns about sustained workforce shortages in cancer services, due to increasing demand for treatment outstripping consultant expansion. To help grow the future workforce, by encouraging medical students and early career doctors to consider a career in medical oncology, the ACP held a recruitment webinar in July 2023. Over 200 registered for the event, with over 100 attending the live webinar. The webinar was recorded and made publicly available to support recruitment into the specialty. The ACP is planning a comprehensive workforce census to capture the medical oncology/chemotherapy prescribing workforce, with the granularity that should be very helpful in future workforce planning.

As in previous years, excellence in research amongst trainees is encouraged by the award of two annual McElwain prizes, one for a clinical project and one for translational research, in addition to a President's Prize. The three prize-winners are invited to present their work to their peers at the annual ACP trainees' weekend in Leeds, in addition to receiving a financial reward.

The ACP continued their series of monthly teaching webinars, started in 2020. The webinars are supported by pharmaceutical sponsorship and continue to attract sizeable attendances and excellent feedback. The recordings of all the webinars are edited and made available free of charge to all ACP members.

The ACP continues to work closely with EBN Health, an experienced healthcare publishing company, to produce and support its publications. These have been very successful, with several of the publications awarded the BMA Oncology Prize. The most recent book, Problem Solving in Interventional Oncology, was published in 2023 and the content was based on the successful meeting on Interventional Oncology, a collaboration with the British Society of Interventional Radiology, held in Leeds in 2021. The ACP and EBN Health have also established a digital platform as an educational resource to benefit members. This allows access to the full searchable content of the ACP/EBN publications and also includes recordings from the teaching webinars.

The ACP has a reciprocal membership agreement with ESMO (European Society for Medical Oncology), and ESMO representatives sit on the ACP Executive Committee. The ACP collaborates closely with ESMO, and ACP members benefit from a reduced membership subscription to ESMO in addition to access to their extensive programme of activities to support career development.

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

The ACP continues to be closely involved with and is a parent body of the UK SACT (Systemic Anti-Cancer Treatment) Board (previously the UK Chemotherapy Board), which provides guidance, oversight and support for the continuing development of systemic therapy services across the UK. The UK SACT Board hosts an annual meeting focused on developing and supporting the delivery of SACT services, which is very well attended. The UK SACT Board has been key in the development and oversight of national standardised SACT regimen-specific and generic consent forms. The aim is to support clinicians throughout the UK in ensuring that all patients are fully informed when consenting to SACT. The UK SACT Board has also established workstreams to undertake audits and produce national guidance and patient-supporting materials to support improvements in the delivery of systemic therapy in the UK. The chairmanship of the UK SACT Board rotates annually among its parent bodies and in 2024 will be chaired by Dr Roshan Agarwal, on behalf of the ACP.

The ACP is also a member of the Inequalities in Health Alliance, a multi-professional collaborative group launched by the RCP in 2020, to campaign for a cross-government strategy to address and reduce health inequalities.

Since 2019, Working Groups from the ACP, the Royal Colleges of Physicians and The Royal College of Radiologists (RCR) have been exploring the benefits - to patients, the NHS and to clinicians – of closer working between the two specialties of Clinical Oncology and Medical Oncology. The initial exploration of closer working and closer alignment in training in clinical oncology and medical oncology resulted in a common first year of training in both specialties, implemented in August 2021. Discussions and consultation with members and other stakeholders continued in 2022 and 2023, with the shared goal of:

- Improving the quality and efficiency of cancer care and patient outcomes in many areas including Acute Oncology (AO).
- Strengthening both specialties by working together and providing a robust, flexible framework for future developments in cancer care.
- Having a stronger joint voice for the two specialties together, increasing their influence for the benefit of services and patients.

After wide ranging analysis and consultations, a Closer Working Group concluded that the best eventual solution would be for Clinical Oncology and Medical Oncology to remain as two separate specialties but to form a new Joint Faculty, hosted within the RCR. Despite this, following a detailed investigation of the current financial, operational and governance issues, it was clear that this was not currently possible. However, the Closer Working Group recommended that Clinical Oncology and Medical Oncology should establish a joint committee to develop plans for closer working in several areas, including policy and strategy, training and education, professional guidance and workforce development. They should work together towards the formation of a Joint Faculty when it became possible to do so, and a template for such a faculty has already been agreed. A Joint Working Group (formed of senior representatives from both the RCR Faculty of Clinical Oncology and the ACP) was therefore established in 2023, with the first meeting held in November 2023.

Financial review

Financially, the ACP's main source of income is from members subscriptions, with additional sponsorship and educational grants from the pharmaceutical industry to support educational activities. SAS is contracted to manage the ACP's educational meetings, in addition to maintaining the membership database and responsibility for the collection of subscription income. It is hoped that this will maximise subscription income going forward. The current account runs in credit. Travel costs incurred by Executive members and secretarial costs have previously been the main expenditures, although travel continued to be severely restricted in 2023, with a move to meetings being held virtually. Further substantial expenditure was on educational events and publishing activities supported by receipt of restricted and unrestricted Educational Grants and sponsorships.

Reserves policy

Reserves Policy

The association ensures there is sufficient money to meet its annual commitments. A separate fund entitled the McElwain Fund also exists for the presentation of prizes and scholarships in respect of studies to advance the objectives of the association.

At the year end unrestricted reserves were £41,262 (2022: £66,691) and restricted reserves were £22,202 (2022: £45,115).

THE ASSOCIATION OF CANCER PHYSICIANS

TRUSTEES REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

Major risks

The trustees have assessed the major risks to which the constitution is exposed, and are satisfied that systems are in place to mitigate exposure to the major risks.

Structure, governance and management

The Association of Cancer Physicians was set up in 1985 and then formally adopted the constitution on 29 March 1993 and was registered by the charity commission on 28 January 1994 (charity number 1032256).

The trustees who served during the year were:

Dr A Jones

Professor R Begent

Recruitment and appointment of trustees

New trustees are appointed by the Executive Committee and 2-3 nominations were made this year who are being approached about serving in this capacity. Particular emphasis is placed upon the appointment of trustees with knowledge and experience relevant to the charity's charitable activities as well as other trustees with the specialty to offer complementary skills eg accounting and marketing.

Public Benefit Statement

Guidance from the Charity Commission has been used to review and develop The Association of Cancer Physicians aims and objectives so that activities are clearly focused to derive good public benefit.

The trustees report was approved by the Board of Trustees.

.....
Dr A Jones

Date:

THE ASSOCIATION OF CANCER PHYSICIANS

INDEPENDENT EXAMINER'S REPORT

TO THE TRUSTEES OF THE ASSOCIATION OF CANCER PHYSICIANS

I report to the trustees on my examination of the financial statements of The Association of Cancer Physicians (the constitution) for the year ended 31 December 2023.

Responsibilities and basis of report

As the trustees of the constitution you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the constitution's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the constitution as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Rouse Partners LLP

55 Station Road
Beaconsfield
Buckinghamshire
HP9 1QL
United Kingdom

Dated:

THE ASSOCIATION OF CANCER PHYSICIANS

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes						
Income and endowments from:							
Donations and legacies	2	49,129	31,965	81,094	43,464	58,750	102,214
Investments	3	-	23	23	-	7	7
Other income	4	849	-	849	997	-	997
Total income		<u>49,978</u>	<u>31,988</u>	<u>81,966</u>	<u>44,461</u>	<u>58,757</u>	<u>103,218</u>
Expenditure on:							
Charitable activities	5	35,407	94,901	130,308	44,047	78,873	122,920
Total expenditure		<u>35,407</u>	<u>94,901</u>	<u>130,308</u>	<u>44,047</u>	<u>78,873</u>	<u>122,920</u>
Net income/(expenditure)		14,571	(62,913)	(48,342)	414	(20,116)	(19,702)
Transfers between funds		(40,000)	40,000	-	-	-	-
Net movement in funds		(25,429)	(22,913)	(48,342)	414	(20,116)	(19,702)
Reconciliation of funds:							
Fund balances at 1 January 2023		66,691	45,115	111,806	66,277	65,231	131,508
Fund balances at 31 December 2023		<u>41,262</u>	<u>22,202</u>	<u>63,464</u>	<u>66,691</u>	<u>45,115</u>	<u>111,806</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

THE ASSOCIATION OF CANCER PHYSICIANS

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Current assets					
Debtors	10	40,276		24,094	
Cash at bank and in hand		30,484		90,490	
		<u>70,760</u>		<u>114,584</u>	
Creditors: amounts falling due within one year	11	(7,296)		(2,778)	
Net current assets			<u>63,464</u>		<u>111,806</u>
The funds of the constitution					
Restricted income funds	12		22,202		45,115
Unrestricted funds	13		41,262		66,691
			<u>63,464</u>		<u>111,806</u>

The financial statements were approved by the trustees on

.....
Dr A Jones

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Company information

The Association of Cancer Physicians is an unincorporated association, constituted under a Governing Document dated 29 March 1993 and is a registered charity in the United Kingdom reference 1032256. The address of the registered office is given on the legal and administrative information page of these financial statements.

1.1 Accounting convention

These accounts have been prepared in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102"), "Accounting and Reporting by Charities" the Statement of Recommended Practice for charities applying FRS 102, the Charities Act 2011 and UK Generally Accepted Accounting Practice as it applies from 1 January 2015. The constitution has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows. The constitution is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the constitution. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the constitution has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Incoming resources

Income is recognised when the constitution is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

All incoming resources are included in the Statement of Financial Activities (SOFA) when receivable.

Grants receivable are recognised when all performance conditions are satisfied and they have been received.

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Resources expended

All expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all costs related to the category. Expenditure is recognised where there is a legal or constructive obligation to make payments to third parties, it is probable that the settlement will be required and the amount of the obligation can be measured reliably. It is categorised under the following headings:

Expenditure on charitable activities includes support and governance costs which are incurred in running the charity.

Support costs are those that assist the work of the charity and include office costs, governance costs and administrative costs. They are incurred directly in support of expenditure on the objects of the charity and allocated to expenditure on charitable activities on a basis consistent with use of the resources.

All expenditure is accounted for on an accruals basis and includes irrecoverable VAT. Direct costs are allocated to the particular activity.

1.6 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.7 Financial instruments

The constitution has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the constitution's balance sheet when the constitution becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are measured at transaction price.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are recognised at transaction.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities.

Derecognition of financial liabilities

Financial liabilities are derecognised when the constitution's contractual obligations expire or are discharged or cancelled.

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

2 Donations and legacies

	Unrestricted funds	Restricted funds	Total 2023	Total 2022
	£	£	£	£
Grants	12,029	31,965	43,994	73,594
Membership fees & sponsorships	37,100	-	37,100	28,620
	<u>49,129</u>	<u>31,965</u>	<u>81,094</u>	<u>102,214</u>
For the year ended 31 December 2022	<u>43,464</u>	<u>58,750</u>		<u>102,214</u>

3 Income from investments

	Restricted funds 2023	Restricted funds 2022
	£	£
Interest receivable	<u>23</u>	<u>7</u>

4 Other income

	Unrestricted funds 2023	Unrestricted funds 2022
	£	£
Royalties	<u>849</u>	<u>997</u>

5 Charitable activities

	2023	2022
	£	£
Prizes	3,500	3,000
Meeting and Travel Expenses	83,958	79,123
Publishing Services	12,500	22,500
	<u>99,958</u>	<u>104,623</u>
Share of governance costs	<u>30,350</u>	<u>18,297</u>
	<u>130,308</u>	<u>122,920</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

6 Support costs

	Support costs	Governance costs	2023	2022	Basis of allocation
	£	£	£	£	
Secretarial Services	-	14,607	14,607	15,459	Governance
Independent examination	-	2,775	2,775	3,150	Governance
Sundry expenses	-	858	858	-	Governance
Bank charges	-	57	57	70	Governance
	<u>-</u>	<u>18,297</u>	<u>18,297</u>	<u>18,679</u>	
Analysed between					
Charitable activities	<u>-</u>	<u>30,350</u>	<u>30,350</u>	<u>18,297</u>	

7 Trustees

None of the trustees (or any persons connected with them) received any remuneration during the year.

8 Employees

The average monthly number of employees during the year was:

	2023	2022
	Number	Number
Total	<u>-</u>	<u>-</u>

There were no employees whose annual remuneration was more than £60,000.

9 Taxation

The charity is exempt from taxation on its activities because all its income is applied for charitable purposes.

10 Debtors

	2023	2022
	£	£
Amounts falling due within one year:		
Trade debtors	9,000	6,000
Other debtors	28,705	18,094
Prepayments and accrued income	2,571	-
	<u>40,276</u>	<u>24,094</u>

11 Creditors: amounts falling due within one year

	2023	2022
	£	£
Accruals and deferred income	<u>7,296</u>	<u>2,778</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

12 Restricted funds

The restricted fund in relation to the McElwain fund is a separate fund that exists for the award of prizes and scholarships in respect of educational and research studies to advance the objects of the association.

The New Consultants Weekend fund was set up to specifically support senior trainees and consultants in the first 5 years of their appointments. An annual event is held to allow discussions both amongst themselves and with invited more senior mentors about topics facing them at this point in their career.

The Bagshawe Lecture Fund was established following a donation by the trustees of the Post Natal Chorionepithelioma Trust (PNCT) when the charity was dissolved in 2018. The funds support an annual named “Bagshawe” lecture. In 2023 the lecture was given by Dr Tim Cooksley, President of the Society for Acute Medicine during the ACP/UKAOS meeting in Leeds in November.

The Interventional Oncology Fund was set up to support a joint interdisciplinary meeting held in October 2021 between the ACP and the British Society of Interventional Oncology (BSIR), to highlight some of the new advances in the rapidly expanding field of interventional oncology. The meeting was followed up with a book “Problem Solving in Interventional Oncology”, published in June 2023.

The Advances in Biotherapies Workshop Fund supported a very successful one-day meeting held in Leeds in October 2022. The workshop showcased some of the recent advances in the rapidly developing field of biotherapies. Presentations from leading experts were complemented with case-based interactive panel discussions. Pharmaceutical sponsorship enabled ACP members to attend the event free of charge.

The Acute Oncology Workshop Fund was set up to support a one-day meeting in Leeds, “Acute Oncology: Challenges and Opportunities”, a joint collaboration with the UK Acute Oncology Society, followed by the annual trainees weekend, which also had an acute oncology focus. This meeting brought together a panel of multidisciplinary speakers to address some of the dilemmas faced by everyone working in Acute Oncology. There was a focus on how acute oncology fits into the medical oncology curriculum and the current NHS landscape, and how best to support the continued development of acute oncology services across the UK.

The ACP Problem Solving in Oncology Webinar fund was set up to support a series of monthly teaching webinars which were launched in October 2020. Sponsored by pharmaceutical companies and hosted on Zoom, the live webinars were initially started to provide additional teaching to compensate for the reduction in local, regional and national educational opportunities during the COVID-19 pandemic. Due to their popularity, the live webinars continue on a monthly basis and are recorded, with the recordings available free of charge to ACP members.

	Movement in funds			Movement in funds				Balance at 31 December 2023
	Balance at 1 January 2022	Incoming resources	Resources expended	Balance at 1 January 2023	Incoming resources	Resources expended	Transfer from unrestricted funds	
	£	£	£	£	£	£	£	£
McElwain	4,991	7	(3,000)	1,998	23	(3,000)	-	(979)
New Consultants Weekend	11,915	-	-	11,915	14,500	(17,948)	-	8,467
Bagshawe Lecture	29,384	-	(372)	29,012	-	(7,500)	-	21,512
BSIR Interventional Oncology Study Day and Publication	17,192	-	(5,000)	12,192	-	-	-	12,192

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

12 Restricted funds

(Continued)

Oncology Webinar Series	1,749	-	(7,941)	(6,192)	2,500	(4,414)	-	(8,106)
Advances in Biotherapies Workshop	-	58,750	(62,560)	(3,810)	-	-	-	(3,810)
Acute Oncology Workshop	-	-	-	-	13,905	(60,090)	40,000	(6,185)
ACP Dinner	-	-	-	-	1,060	(1,949)	-	(889)
	<u>1,749</u>	<u>58,750</u>	<u>(70,501)</u>	<u>(10,002)</u>	<u>17,465</u>	<u>(66,453)</u>	<u>40,000</u>	<u>(16,380)</u>
	<u>65,231</u>	<u>58,757</u>	<u>(78,873)</u>	<u>45,115</u>	<u>31,988</u>	<u>(94,901)</u>	<u>40,000</u>	<u>22,202</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

13 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 January 2023	Incoming resources	Resources expended	Transfers	At 31 December 2023
	£	£	£	£	£
General funds	66,691	49,978	(35,407)	(40,000)	41,262
	<u>66,691</u>	<u>49,978</u>	<u>(35,407)</u>	<u>(40,000)</u>	<u>41,262</u>
Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
General funds	66,277	44,461	(44,047)	-	66,691
	<u>66,277</u>	<u>44,461</u>	<u>(44,047)</u>	<u>-</u>	<u>66,691</u>

14 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Current assets/(liabilities)	41,262	22,202	63,464
	<u>41,262</u>	<u>22,202</u>	<u>63,464</u>
	<u>41,262</u>	<u>22,202</u>	<u>63,464</u>
	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
At 31 December 2022:			
Current assets/(liabilities)	66,691	45,115	111,806
	<u>66,691</u>	<u>45,115</u>	<u>111,806</u>
	<u>66,691</u>	<u>45,115</u>	<u>111,806</u>

THE ASSOCIATION OF CANCER PHYSICIANS

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

15 Related party transactions

There were no disclosable related party transactions during the year.